Medivation and Astellas Pharma
Launch Date: September 2012
First-Year Sales: $71.5 million (partial 2012)
First-Half 2013 Sales: $157.8 million
Analyst Estimate for 2018: $2.769 million
The FDA approved the highly anticipated prostate cancer drug Xtandi last year three months ahead of schedule. The drug from Medivation ($MDVN) and Astellas Pharma, known experimentally as MDV3100, was approved for men who have already had chemo.
Like Johnson & Johnson's ($JNJ) Zytiga, which hit the market more than a year earlier, Xtandi is a pill. Both of them also interfere with the testosterone that can feed the disease, although they operate in different ways. While it followed Zytiga onto the market, some analysts think Xtandi will overtake its rival in sales and have pegged peak earnings at more than $2 billion a year.
While their survival data is fairly similar, Xtandi doesn't have some of the safety issues associated with Zytiga. Unlike the J&J drug, patients on Xtandi don't have to take prednisone and deal with the risk of elevated blood pressure from the corticosteroid.
Xtandi is priced at a premium compared to the J&J drug: $7,450 per month for Xtandi, compared to $5,500 a month for Zytiga.
In about four months on the market last year, Xtandi recorded $71.5 million in revenues but then turned in $157.8 million in the first half of this year. Still, that is a far cry from the $739 million Zytiga sold in the first half of this year. Zytiga's sales have been propelled by a new FDA approval late last year as a first-line treatment against prostate cancer, an indication that Medivation and Astellas Pharma are expected to seek for Xtandi.
Special Report: Top 10 Late-Stage Cancer Drugs of 2012 - Enzalumatide
Zytiga, Xtandi will help pump prostate cancer market to $9.1B
J&J's Zytiga gets early challenge from Medivation's new pill
Medivation wins FDA OK for blockbuster prostate cancer drug
Abiraterone vs. MDV3100: A prostate cancer drug showdown
-- Eric Palmer (email | Twitter)